Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Michael Benatar; Joanne Wuu; Peter M. Andersen; Robert C. Bucelli; Jinsy A. Andrews; Markus Otto; Nita A. Farahany; Elizabeth A. Harrington; Weiping Chen; Adele A. Mitchell; Toby Ferguson; Sheena Chew; Liz Gedney; Sue Oakley; Jeong Heo; Sowmya Chary; Laura Fanning; Danielle Graham; Peng Sun; Yingying Liu; Janice Wong; Stephanie Fradette

ArticleOPEN ACCESS

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Neurotherapeutics

DOI: 10.1007/s13311-022-01286-9

5Citations

24Readers

Abstract

Due to an error during production, captions for Fig. 1, Fig. 5 and Fig. 6 in this article were formatted in a confusing manner in this article as originally published. The original article has been corrected.

Cite

CITATION STYLE

APA

Benatar, M., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., Otto, M., … Fradette, S. (2022, September 1). Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4). Neurotherapeutics. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s13311-022-01286-9

Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Abstract

Cite

Register to see more suggestions